Clinical trials: Infection Prevention and Control
Teen Pregnancy, Pregnancy in Adolescence
Future Foundation 2.0 Personal Responsibility Education Innovative Strategies (PREIS) Program
This study uses a randomized controlled trial (RCT) design to evaluate the impacts of the Future Foundation (FF) 2.0 Personal Responsibility Education Innovative Strategies (PREIS) program on reducing students' sexual activity…
- Conditions
- Teen Pregnancy, Pregnancy in Adolescence, Teen Pregnancy Prevention, Pregnancy Prevention
- Trial name
- NCT03729726
- Testing
- Future Foundation 2.0 PREIS Program
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Metis Associates, Inc.
Bacterial Vaginosis
Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis
The purpose of this study is to demonstrate if the use of Dermacyd can avoid the recurrence of bacterial vaginosis after three months of the standard treatment.
- Trial name
- NCT00556179
- Testing
- Lactoserum (Dermacyd Femina®)
- Where
- Brazil
- Volunteers
- 122 people
- Sponsor
- Sanofi
Respiratory Syncytial Virus Infection Prevention
A Study of an Ad26.RSV. preF-based Vaccine in Adults Aged 18 to 59 Years, Including Adults at High Risk for Severe RSV Infection
The purpose of the study is to investigate the safety and immunogenicity of the Ad26.RSV.preF based vaccine in adults 18 to 59 years of age who are healthy or at risk for severe Respiratory Syncytial Virus (RSV) disease, compared…
- Trial name
- NCT05070546
- Testing
- Ad26.RSV.preF-based Vaccine
- Where
- 23 sites in United States, Belgium and 3 more
- Volunteers
- 1,124 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
COVID-19 Pandemic
Intranasal INNA-051 for Prevention of COVID-19 in Adults
This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in adults following household contact with an individual with RT-PCR confirmed SARS CoV-2 infection.
- Trial name
- NCT05118763
- Testing
- INNA-051
- Volunteers
- healthy volunteers welcome
- Sponsor
- ENA Respiratory Pty Ltd
Infection Prophylaxis
Pharmacokinetics, Pharmacodynamics and Safety Evaluation of SAR279356 in Intensive Care Unit Mechanically Ventilated Patients
Primary Objective: To determine the pharmacokinetics (PK) of a single intravenous (IV) dose of SAR279356 administered to intensive care unit (ICU) patients on mechanical ventilation Secondary Objectives: To determine the safety…
- Trial name
- NCT01389700
- Testing
- SAR279356
- Where
- 6 sites in United States
- Volunteers
- 7 people
- Sponsor
- Sanofi
Respiratory Tract Infections, Wheezing Lower Respiratory Illness
OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness
This study will assess the efficacy and safety of OM-85 compared to placebo in reducing the number of respiratory tract infections (RTIs) in children aged between 6 months and 5 years.
- Trial name
- NCT05677763
- Testing
- OM-85
- Where
- 42 sites in Germany, Hungary and 4 more
- Volunteers
- 525 people
- Sponsor
- OM Pharma SA
Pneumonia, Pneumococcal, Pneumococcal Infections
Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults
The purpose of this study is to assess the efficacy of 13-valent pneumococcal conjugate vaccine in the prevention of the first episode of vaccine-type pneumococcal community-acquired pneumonia in adults.
- Conditions
- Pneumonia, Pneumococcal, Pneumococcal Infections, 13-valent Pneumococcal Vaccine
- Trial name
- CAPITA (NCT00744263)
- Testing
- VACCINE: 13-valent pneumococcal conjugate vaccine
- Where
- 159 sites in Netherlands
- Volunteers
- 84,496 people, healthy volunteers welcome
- Sponsor
- Pfizer
Respiratory Syncytial Virus Infections
A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Preterm Infants.
The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics (PK), and antidrug antibody (ADA) response for MEDI8897 in healthy preterm infants who are between 29 and 35 weeks gestational age (GA) and entering…
- Trial name
- MEDI8897 Ph2b (NCT02878330)
- Testing
- MEDI8897
- Where
- 161 sites in United States, Argentina and 21 more
- Volunteers
- 1,453 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Clostridium Difficile, Clostridium Infections
A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI
A Phase 2b Parallel-Group, Double-Blind, Placebo-Controlled, Multicenter Study of SYN-004 Compared to Placebo for the Prevention of Clostridium difficile Infection (CDI) in Hospitalized Patients receiving IV ceftriaxone with a…
- Trial name
- NCT02563106
- Testing
- SYN-004
- Where
- 43 sites in United States, Bulgaria and 5 more
- Volunteers
- 413 people
- Sponsor
- Theriva Biologics, Inc.
COVID-19, SARS-CoV2
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
The purpose of this study is to evaluate whether LY3819253 given alone and with LY3832479 prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease - 2019 (COVID-19).
- Trial name
- BLAZE-2 (NCT04497987)
- Testing
- Bamlanivimab, Etesevimab
- Where
- 27 sites in United States
- Volunteers
- 1,180 people
- Sponsor
- Eli Lilly and Company
COVID-19, SARS-CoV-2
Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults
The aim of the study is to assess the safety, and immunogenicity of AZD2816 for the prevention of coronavirus disease 2019 (COVID-19).
- Trial name
- AZD2816 (NCT04973449)
- Testing
- AZD1222, AZD2816
- Where
- 35 sites in Brazil, Poland and 2 more
- Volunteers
- 2,843 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Prevention of Infection With HIV-1
Safety Study of Ibalizumab Subcutaneous Injection in Healthy Volunteers
The is a blinded safety study of ibalizumab given by subcutaneous injection in sequentially increasing dose-groups of at-risk, HIV-negative, healthy volunteers.
- Trial name
- TMB-108 (NCT01292174)
- Where
- 6 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- TaiMed Biologics Inc.
Prevention of Meningococcal Infection
Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in Healthy Children
Immunogenicity, Safety, Tolerability and Ability to Prime for Memory of Meningococcal C Conjugate Vaccine in healthy children
- Trial name
- NCT00311415
- Testing
- Meningococcal C conjugate vaccine
- Where
- 2 sites in Germany, Poland
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
A Study of Arbidol (Umifenovir) for Treatment and Prophylaxis of Influenza and Common Cold
The purpose of this study is to determine whether Arbidol (Umifenovir) is effective in the treatment and Prophylaxis of Influenza and Common Cold
- Trial name
- ARBITR (NCT01651663)
- Testing
- Arbidol (Umifenovir)
- Where
- 2 sites in Russia
- Volunteers
- 840 people
- Sponsor
- Pharmstandard
Meningococcal Disease, Meningococcal Meningitis
Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines
This study will evaluate safety, tolerability, and immunogenicity of a booster dose of a meningococcal vaccine formulation in adolescents.
- Trial name
- NCT01367158
- Testing
- Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine, Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Tdap
- Where
- 7 sites in Chile, Colombia and 1 more
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
COVID-19
A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention
A multicenter, randomized, double-blind, placebo-controlled, study to evaluate the efficacy and safety of oral ivermectin tablets versus placebo for COVID-19 prophylaxis
- Trial name
- SAIVE (NCT05305560)
- Testing
- Ivermectin Tablets
- Where
- Bulgaria
- Volunteers
- 400 people
- Sponsor
- MedinCell S.A